

DOI: 10.4274/jcrpe.galenos.2021.2021.0141

## Case report

# Central Precocious Puberty in a Boy with Pseudohypoparathyroidism Type 1A due to a Novel *GNAS* Variant, Who Had Congenital Hypothyroidism as the First Manifestation

Wankanit S et al. CPP and Pseudohypoparathyroidism

Somboon Wankanit, Pat Mahachoklertwattana, Thipwimol Tim-Aroon, Kinnaree Sorapipatcharoen, Preamrudee Poomthavorn  
Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

### What is already known on this topic?

Resistance to multiple hormones as evidenced by pseudohypoparathyroidism, hypothyroidism and hypogonadism is characteristics of pseudohypoparathyroidism type 1A (PHP1A). Mild congenital hypothyroidism could be manifested as the first and only clinical presentation of patients with PHP1A.

### What this study adds?

Boys with PHP1A might develop central precocious puberty despite having multiple hormone resistance.

### Abstract

Pseudohypoparathyroidism type 1A (PHP1A) is a disorder of multiple hormone resistance, mainly parathyroid hormone. It is associated with Albright hereditary osteodystrophy phenotypes. Patients with PHP1A may initially present with hypothyroidism during infancy and later develop typical PHP1A characteristics during their childhood. Central precocious puberty (CPP) is extremely rare among PHP1A patients in whom gonadotropin resistance is more usual. This study reported a 9.5-year-old boy with congenital hypothyroidism who developed hypocalcemia secondary to pseudohypoparathyroidism. He had relatively short stature with height standard deviation score of -0.9. Obesity had been noted since the age of 2 years. At the presentation of pseudohypoparathyroidism, pubertal-sized testes of 10 mL were observed, and CPP was documented with serum testosterone concentration of 298 ng/dL (normal for Tanner stage III, 100-320), luteinizing hormone of 3.9 IU/L (normal, 0.2-5.0), and follicle-stimulating hormone of 4.8 IU/L (normal, 1.2-5.8). Pituitary magnetic resonance imaging was unremarkable. Genetic analysis confirmed the diagnosis of PHP1A with a novel heterozygous missense variant of *GNAS* gene in the exon 13, c.1103A>G (p.Asp368Gly). Awareness of PHP1A diagnosis in patients with congenital hypothyroidism and early childhood-onset obesity is crucial for early diagnosis. Apart from multiple hormone resistance, CPP could be manifested in patients with PHP1A.

**Keywords:** pseudohypoparathyroidism, precocious puberty, hypothyroidism

Preamrudee Poomthavorn, M.D. Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Rama 6 Road, Bangkok 10400, Thailand  
preamrudee.poo@mahidol.ac.th  
+662 201 1394  
0000-0001-6161-6210  
18.05.2021  
24.06.2021

**Published:** 6 August 2021

### Introduction

Pseudohypoparathyroidism (PHP) type 1A (PHP1A) is a disorder of multiple hormone resistance in which a decreased responsiveness to parathyroid hormone (PTH) leading to hypocalcemia and hyperphosphatemia, is a main defect (1). It is caused by heterozygous loss-of-function variants in the coding sequence of *GNAS* gene that cause defects in  $\alpha$ -subunit of the stimulatory G protein ( $G_{s\alpha}$ ) (2). Resistance to other hormones which includes thyroid-stimulating hormone (TSH), gonadotropins and growth hormone (GH)-releasing hormone, causes hypothyroidism, hypogonadism and GH deficiency, respectively (2). In addition, PHP1A is associated with Albright hereditary osteodystrophy (AHO) phenotypes including short stature, brachydactyly, obesity, round face, and ectopic ossifications (1,2). TSH resistance was frequently described as the presenting feature of PHP1A with diverse severity from isolated hyperthyrotropinemia to overt hypothyroidism, and might be presented at birth as congenital hypothyroidism or later during infancy and childhood (2,3). The diagnosis of PHP1A was often delayed in patients who presented with isolated TSH resistance, until other manifestations became apparent (4-7).

Some PHP1A patients also demonstrated elevated gonadotropin levels which represents gonadotropin resistance (8-12). This finding was mainly reported in female PHP1A patients who presented with either amenorrhea or oligomenorrhea (9-11). In contrast, male PHP1A patients were rarely reported to have gonadotropin resistance (10-12).

Central precocious puberty (CPP) which is theoretically a condition opposite to gonadotropin resistance, is unlikely to be present in PHP1A patients. However, to our knowledge, CPP was previously reported in 2 PHP boys who had PTH as the only hormone resistance (13,14). Herein, we reported a boy with PHP1A who was diagnosed with isolated

hyperthyrotropinemia during infancy, and developed symptomatic hypocalcemia secondary to PHP1A later in his childhood at which time CPP was also diagnosed.

### Case report

A 9.5-year-old boy who had been diagnosed as having mild congenital hypothyroidism since the age of 11 months presented to our hospital for the first time with viral infection and tetany. Physical examination revealed body temperature of 38.8°C, heart rate of 82 beats per minute, blood pressure of 97/61 mmHg, height of 128 cm (-0.9 standard deviation score, SDS), weight of 38 kg (+1.8 SDS) and body mass index of 23.2 kg/m<sup>2</sup> (+2.6 SDS). Carpopedal spasm and positive Chvostek's sign were noted. He had round face and short fourth and fifth metacarpal bones. No subcutaneous calcification was observed. Chest, abdominal and neurological examinations were unremarkable. Investigations for his tetany revealed a finding which was consistent with PTH resistance or PHP, including hypocalcemia, hyperphosphatemia and elevated intact PTH level concomitant with hypocalcemia and high tubular reabsorption of phosphate (Table 1). His clinical presentations including AHO phenotypes (obesity, round face, short metacarpal bones and relatively short stature) and PHP led to the provisional diagnosis of PHP1A. Supportive treatment for viral infection was administered. Hypocalcemia secondary to PHP was initially treated with intravenous calcium gluconate concomitant with oral calcium carbonate and calcitriol. Tetany was resolved following intravenous calcium gluconate treatment and normalization of serum calcium and phosphorus concentrations was gradually achieved with oral calcium carbonate and calcitriol.

Regarding his past medical and congenital hypothyroidism history, he was born at 35 weeks of gestation with a birth weight of 2.6 kg (+0.1 SDS) and length of 47 cm (+0.4 SDS). His developmental milestones were normal. He had a positive serum TSH screening level of 29 mU/L (normal, <25). Subsequent thyroid functions at ages 11 days to 7 months showed serum TSH levels of 5.6-12.1 mU/L (normal, 0.7-4.2) and free thyroxine (T<sub>4</sub>) levels of 1.1-1.2 ng/dL (normal, 0.9-1.7), indicating isolated hyperthyrotropinemia. Levothyroxine was not started until the age of 11 months when his TSH level rose to 16.2 mU/L with normal free T<sub>4</sub> of 0.9 ng/dL. Free T<sub>4</sub> and TSH were normalized within 4 weeks following levothyroxine treatment. Taken together, congenital hypothyroidism or TSH resistance, one of the PHP1A phenotypes, was the first manifestation of PHP in this patient.

His growth trajectory had been tracking along the 75<sup>th</sup> percentile for weight and the 3<sup>rd</sup> percentile for height since he was 2 years of age. His mid-parental height was 159 cm (-2.0 SDS). His height velocity had strikingly increased by 9.5 cm during the past year. Pubertal assessment demonstrated testicular size of 10 mL, penile length of 7 cm and Tanner stage III pubic hair. Based on his height velocity and secondary sex characteristics, pubertal onset had presumably begun before 9 years of age. Therefore, the findings were consistent with gonadotropin-dependent precocious puberty or CPP. The diagnosis was confirmed by the findings of pubertal levels of serum testosterone, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and advanced bone age (Table 1). Pituitary magnetic resonance imaging was normal. He was commenced on depot gonadotropin-releasing hormone analog to preserve final adult height.

A novel heterozygous missense variant of *GNAS* gene (NM\_000516.5) in the exon 13, c.1103A>G (p.Asp368Gly) was identified in the patient. The variant was classified as likely pathogenic based on the American College of Medical Genetics criteria (15). The variant has not been reported in individuals with PHP1A or in the gnomAD, ExAC and in-house Thai Exome databases. Multiple computer prediction algorithms including SIFT, DANN, PrimateAI REVEL, MutationTaster, MVP, Polyphen2HVAR, BayesDel\_addAF, DEOGEN2, EIGEN, FATHMM-MKL, LIST-S2, M-CAP, and MutationAssessor classified the variant as damaging or deleterious. The sequence data has been submitted to the GenBank database under accession number MW503931.

Maternally-inherited heterozygous inactivating *GNAS* mutation is usually the cause of PHP1A. His mother's height was 140 cm (-3.6 SDS) and she had short fourth and fifth metacarpal bones. Her serum calcium, phosphorus and intact PTH levels were normal at 9.2 mg/dL (normal, 8.5-10.5), 3.2 mg/dL (normal, 2.4-4.4) and 54 pg/mL (normal, 10-65), respectively. Since AHO phenotypes were observed in the absence of PTH resistance, the diagnosis of pseudopseudohypoparathyroidism was likely in his mother. Genetic testing revealed the same variant in *GNAS* gene as found in the patient.

### Ethics

The report was approved by the Ethics Committee of the Faculty of Medicine Ramathibodi Hospital, Mahidol University (Date 23 February 2021, MURA 2021/161) and conformed to the Declaration of Helsinki.

### Informed consent

Informed assent and consent were obtained from the patient and his parents, respectively.

### Discussion

The patient in this report had mild congenital hypothyroidism as the first manifestation of PHP1A. In fact, hyperthyrotropinemia representing TSH resistance, is a common finding and could be the earliest hormonal dysfunction in PHP1A patients, because elevated TSH concentration might be detected at the time of neonatal screening (2-5). Unlike resistance to TSH, PTH resistance which is the hallmark of PHP1A, is usually manifested after the first few years of life due to gradual silencing of paternal G<sub>s</sub>α in the renal proximal tubule (4). As a result, the diagnosis of PHP1A is often delayed especially in patients with non-specific features such as obesity or short stature (2,4-7). Childhood obesity was proposed as an early clinical sign of PHP1A as it might develop in very early life and could even be recognized before any other endocrine disturbances (2,5). Our patient developed obesity since the age of 2 years and later developed the symptoms of PTH resistance at the age of 9.5 years. Therefore, PHP1A diagnosis should be suspicious in children who present with isolated hyperthyrotropinemia or mild congenital primary hypothyroidism and obesity early in life to avoid delayed diagnosis.

Gonadotropin resistance was described in patients with PHP1A (2,3,7). Delayed or incomplete puberty with elevated gonadotropin levels could thus be one of the PHP1A phenotypes. Symptomatic gonadotropin resistance was more commonly detected in female PHP1A patients while elevation of gonadotropin levels without symptoms was rarely reported in male PHP1A patients (2,3,8-12). Interestingly, our patient developed CPP instead which is exceptionally rare among patients with PHP1A. To our knowledge, there have been only two male PHP patients with CPP reported in the English literature (Table 1) (13,14). Both of them and our patient had CPP at the presentation of PHP. One patient had clinical features of PHP1A and

the diagnosis was confirmed by demonstrating a heterozygous frameshift variant in the exon 7 of *GNAS* gene (13). The other patient manifested PTH resistance in the absence of AHO phenotypes; PHP type 1B, the disease associated with epigenetic alterations at *GNAS* locus, was likely the diagnosis (14). Hence, CPP could be manifested regardless of the type of genetic defect underlying PHP. The mechanism of CPP remains unclear. In parallel with PHP patients who developed CPP, CPP was previously described in girls with Turner syndrome who commonly have ovarian failure (16,17). Functioning ovarian tissue which is infrequently present in girls with Turner syndrome and could be responsive to FSH surge preceding the ovarian failure may be the cause of CPP found in Turner syndrome patients (16). Similarly, CPP in boys with PHP1A might be mediated by testicular androgen production in response to elevated gonadotropin levels during their childhood before developing partial gonadotropin resistance later in life. Nevertheless, coincidental idiopathic CPP in our patient could not be excluded. Idiopathic CPP in girls is indeed much more common than in boys (18). Interestingly, to our knowledge, CPP in girls with PHP1A has not been reported. This might be the gender discordance of resistance to gonadotropins in patients with PHP1A. Inactivating mutation of  $G_s\alpha$ -coupled receptor along hypothalamic-pituitary-gonadal axis that causes CPP has not been identified. Indeed,  $G_s\alpha$ -coupled receptor has not been depicted as a part of the neuroendocrine regulators of male puberty (19).

In conclusion, isolated hyperthyrotropinemia presenting with congenital hypothyroidism could be the first manifestation of PHP1A. Apart from the typical gonadotropin resistance, CPP could also be found in male PHP1A patients.

#### Authorship contributions

S.W., P.M., and P.P. designed the work, collected, analyzed and interpreted data for the work, and drafted the article. T.T. and K.S. analyzed and interpreted genetic testing data. All authors read and approved the final article.

#### References

- Mantovani G, Bastepe M, Monk D, de Sanctis L, Thiele S, Ahmed SF, Bufo R, Choplin T, De Filippo G, Devernois G, Eggermann T, Elli FM, García Ramirez A, Germain-Lee EL, Groussin L, Hamdy N, Hanna P, Hiort O, Jüppner H, Kamenický P, Knight N, Le Norcy E, Lecumberri B, Levine MA, Mäkitie O, Martin R, Martos-Moreno GÁ, Minagawa M, Murray P, Pereda A, Pignolo R, Rejnmark L, Rodado R, Rothenbuhler A, Saraff V, Shoemaker AH, Shore EM, Silve C, Turan S, Woods P, Zillikens MC, Perez de Nanclares G, Linglart A. Recommendations for diagnosis and treatment of pseudohypoparathyroidism and related disorders: an updated practical tool for physicians and patients. *Horm Res Paediatr* 2020;93:182-196.
- Mantovani G, Bastepe M, Monk D, de Sanctis L, Thiele S, Usardi A, Ahmed SF, Bufo R, Choplin T, De Filippo G, Devernois G, Eggermann T, Elli FM, Freson K, García Ramirez A, Germain-Lee EL, Groussin L, Hamdy N, Hanna P, Hiort O, Jüppner H, Kamenický P, Knight N, Kottler ML, Le Norcy E, Lecumberri B, Levine MA, Mäkitie O, Martin R, Martos-Moreno GÁ, Minagawa M, Murray P, Pereda A, Pignolo R, Rejnmark L, Rodado R, Rothenbuhler A, Saraff V, Shoemaker AH, Shore EM, Silve C, Turan S, Woods P, Zillikens MC, Perez de Nanclares G, Linglart A. Diagnosis and management of pseudohypoparathyroidism and related disorders: first international consensus statement. *Nat Rev Endocrinol* 2018;14:476-500.
- Mantovani G. Pseudohypoparathyroidism: diagnosis and treatment. *J Clin Endocrinol Metab* 2011;96:3020-3030.
- Turan S, Fernandez-Rebollo E, Aydin C, Zoto T, Reyes M, Bounoutas G, Chen M, Weinstein LS, Erben RG, Marshansky V, Bastepe M. Postnatal establishment of allelic *Gos* silencing as a plausible explanation for delayed onset of parathyroid hormone resistance owing to heterozygous *Gos* disruption. *J Bone Miner Res* 2014;29:749-760.
- Kayemba-Kay's S, Tripon C, Heron A, Hindmarsh P. Pseudohypoparathyroidism type 1A-subclinical hypothyroidism and rapid weight gain as early clinical signs: a clinical review of 10 cases. *J Clin Res Pediatr Endocrinol* 2016;8:432-438.
- Picard C, Decrey A, Guenet D, Bursztejn AC, Toledano D, Richard N, Kottler ML. Diagnosis and management of congenital hypothyroidism associated with pseudohypoparathyroidism. *Horm Res Paediatr* 2015;83:111-117.
- Linglart A, Levine MA, Jüppner H. Pseudohypoparathyroidism. *Endocrinol Metab Clin North Am* 2018;47:865-888.
- Linglart A, Carel JC, Garabédian M, Lé T, Mallet E, Kottler ML. *GNAS1* lesions in pseudohypoparathyroidism Ia and Ic: genotype phenotype relationship and evidence of the maternal transmission of the hormonal resistance. *J Clin Endocrinol Metab* 2002;87:189-197.
- Long XD, Xiong J, Mo ZH, Dong CS, Jin P. Identification of a novel *GNAS* mutation in a case of pseudohypoparathyroidism type 1A with normocalcemia. *BMC Med Genet* 2018;19:132.
- Wu YL, Hwang DY, Hsiao HP, Ting WH, Huang CY, Tsai WY, Chen HC, Chao MC, Lo FS, Tsai JD, Yang S, Shih SL, Lin SP, Lin CL, Lee YJ. Mutations in pseudohypoparathyroidism 1a and pseudopseudohypoparathyroidism in ethnic Chinese. *PLoS ONE* 2014;9:e90640.
- Sano S, Nakamura A, Matsubara K, Nagasaki K, Fukami M, Kagami M, Ogata T. (Epi)genotype-phenotype analysis in 69 Japanese patients with pseudohypoparathyroidism type I. *J Endocr Soc* 2018;2:9-23.
- Lee YS, Kim HK, Kim HR, Lee JY, Choi JW, Bae EJ, Oh PS, Park WI, Ki CS, Lee HJ. Identification of a novel mutation in a patient with pseudohypoparathyroidism type Ia. *Korean J Pediatr* 2014;57:240-244.
- Kagami R, Sato T, Ishii T, Araki E, Yamashita Y, Shibata H, Ishihara J, Hasegawa T. Central precocious puberty in a boy with pseudohypoparathyroidism type Ia due to a novel *GNAS* mutation. *Clin Pediatr Endocrinol* 2020;29:89-90.
- Rossodivita A, Miceli Sopo S, D'Alessio E, Valentini P. Gonadotropin-dependent sexual precocity in a boy affected by pseudohypoparathyroidism. *J Pediatr Endocrinol Metab* 2000;13(Suppl 1):845-847.
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehms HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015;17:405-424.
- Sabin MA, Zacharin MR. Precocious puberty in Turner syndrome. *J Paediatr Child Health* 2007;43:776-778.

17. Improda N, Rezzuto M, Alfano S, Parenti G, Vajro P, Pignata C, Salerno M. Precocious puberty in Turner syndrome: report of a case and review of the literature. *Ital J Pediatr* 2012;38:54.
18. Latronico AC, Brito VN, Carel JC. Causes, diagnosis, and treatment of central precocious puberty. *Lancet Diabetes Endocrinol* 2016;4:265-274.
19. Avendaño MS, Vazquez MJ, Tena-Sempere M. Disentangling puberty: novel neuroendocrine pathways and mechanisms for the control of mammalian puberty. *Hum Reprod Update* 2017;23:737-763.

**Table 1. Clinical characteristics of the reported patient and previous reports of boys with pseudohypoparathyroidism (PHP) who had central precocious puberty at the diagnosis of PHP**

Characteristics	This report	Kagami <i>et al.</i> <sup>13</sup>	Rossodivita <i>et al.</i> <sup>14</sup>
Age at diagnosis, years	9.5	10.0	11.5
Height, cm (SDS)	128 (-0.9)	138 (+0.2)	157 (+1.9)
Predicted adult height, cm (SDS)	151 (-3.5)	162 (-2.0)	179 (+0.3)
Weight, kg (SDS)	38 (+1.8)	39 (+0.7)	46 (+1.2)
Body mass index, kg/m <sup>2</sup> (SDS)	23.2 (+2.6)	20.2 (+1.6)	18.9 (+0.7)
Bone age, years	13.0	13.0	13.5
Testicular volume, mL	10	6-8	12-15
Serum calcium, mg/dL	6.0	5.3	4.2
Serum phosphorus, mg/dL	8.3	11.1	10.3
Serum magnesium, mg/dL	1.7	NA	1.5
Serum intact PTH, pg/mL	137	363	191
Serum 25-hydroxyvitamin D, ng/mL	35	16	20
Serum testosterone, ng/dL	298	250	384
Serum LH, IU/L	3.9 (random)	18.0 (GnRH-stimulated)	2.8 (random), 29.9 (GnRH-stimulated)
Serum FSH, IU/L	4.8 (random)	7.0 (GnRH-stimulated)	6.9 (random), 13.3 (GnRH-stimulated)
Urine calcium	0.01 mg/mg of creatinine (N, 0.03-0.26)	NA	4.9 mg/kg/day (N, 0.8-2.8)
Tubular reabsorption of phosphate, %	97.6	NA	95.0
<i>GNAS</i> variant	c.1103A>G; p.Asp368Gly	c.568dupT; p.Tyr190Leufs*20	NA
Normal range: serum calcium 8.7-10.7 mg/dL, phosphorus 3.3-5.4 mg/dL, magnesium 1.6-2.4 mg/dL, intact PTH 10-65 pg/mL, 25-hydroxyvitamin D 30-100 ng/mL, testosterone (Tanner stage III) 100-320 ng/dL, tubular reabsorption of phosphate 90-95% FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; LH, luteinizing hormone; N, normal; NA, not available; PTH, parathyroid hormone; SDS, standard deviation score			